Human Challenge Studies With Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research

Stanley M. Spinola,1,2 Camilla Broderick,4 Gregory D. Zimet,5 and Mary A. Ott6
1Department of Microbiology and Immunology, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA, 2Department of Medicine, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA, 3Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA, 4The John Jay College of Criminal Justice, New York, New York, USA, 5Department of Pediatrics, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA, 6Center for Bioethics, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA

This manuscript explores the ethics of human inoculation experiments in young healthy adults with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a tool to evaluate vaccine efficacy in the context of the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report, and in the context of dose-response relationships with infectious agents. Despite societal pressure to develop a SARS-CoV-2 challenge model to evaluate vaccines, we argue that there are substantial risks that cannot be adequately defined because the dose of SARS-CoV-2 that causes severe disease in young adults is unknown. In the absence of curative therapy, even if a volunteer consents, longstanding ethical codes governing human subjects research preclude the conduct of such experiments.

Keywords. ethics; human challenge experiments; SARS-CoV-2; vaccines.

We are writing to discuss the ethics of human challenge experiments with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a tool to accelerate vaccine licensure. This approach involves randomizing healthy volunteers (18 to 25 years old) to vaccine or placebo and then infecting all volunteers with SARS-CoV-2 to assess vaccine efficacy [1–3]. The justifications for the development of this model in young healthy adults are that the risks for morbidity and mortality in this age group are negligible, participants have a right to accept such risks “free from paternalistic overreach,” and there is a “societal value of reducing the time required to identify efficacious vaccines against a disease that is creating a massive and relentless daily toll” [1, 4, 5]. Concerns expressed in opposition to this approach have centered around its utilitarian morality, the possible adverse short-term and long-term health outcomes—including death—in the volunteers, the inability to manage risks associated with experimental infection, the adequacy of informed consent, the time required to develop a model, the utility of a model in accelerating vaccine development, and the reduction in confidence in the research community should adverse events occur [6–8].

We recently published a letter voicing some of these concerns [8]. Shortly thereafter, we were invited to participate in a debate with advocates of the human challenge experiments, including 1Day Sooner, an organization that has signed up over 38 000 volunteers from 166 countries to participate in SARS-CoV-2 challenge trials, which have entered the planning stage in the United Kingdom but have yet to receive regulatory approval [9]. 1Day Sooner has received significant coverage, much of it positive, in the news media, including but not limited to stories in National Geographic, the New York Post, and CNBC [10–12]. In preparation for the debate, which was sponsored by the Rikers Debate Project and the Central Synagogue of Manhattan and can be viewed at https://youtu.be/v1XpQK8nkFg, we realized that although there had been a great deal written concerning the ethics of such experiments [2, 3, 13, 14], there had been little direct discussion of whether human challenges with SARS-CoV-2 are compatible with longstanding ethical codes of human subjects research.

There are 3 documents that have long guided human subjects research: the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report. The overarching theme of these documents is that as physicians and scientists, we are obligated to protect individuals from experiments that might benefit society but harm an individual.

The Nuremberg Code, written in 1947 in response to experimentation done on prisoners in concentration camps in World War II, states that “no experiment...
should be conducted where there is an a priori reason to believe that death or disabling injury will occur; except perhaps in those experiments where the experimental physicians also serve as subjects” [15]. The Declaration of Helsinki, first published in 1964 and primarily directed to physicians, rejects even that exception [16]. The Declaration states that physicians should only engage in research that safeguards the health of participants; the goal of new knowledge “can never take precedence over the rights and interests of individual research subjects” and that “the responsibility for the protection of research subjects must always rest with the physician and never with the research subjects, even though they have given consent.” The Declaration goes on to state that “physicians may not be involved in a research study involving human subjects unless they are confident that the risks have been adequately addressed and can be successfully managed.” Finally, the Belmont Report, published in 1979 in response to the Tuskegee syphilis study, includes the concept of Beneficence: do no harm and maximize possible benefits [17]. For healthy people who are experimentally infected with SARS-CoV-2 or any other infectious agent, there is potential harm and no benefit. Because there is no benefit, the ethical standard for human inoculation experiments is that the disease must be entirely self-limited or there must be a curative therapy [13, 18], which currently does not exist for SARS-CoV-2.

Those who have advocated for SARS-CoV-2 challenges have stated that the risks of morbidity and mortality in young healthy persons are negligible, based on extrapolated infection rates, and therefore such infections are permissible [1]. Those in opposition have stated that the risks of severe illness, death, protracted symptoms, and postinfectious complications such as thromboembolic events, prolonged pulmonary, cardiac, or renal dysfunction and cognitive impairment are substantial, based on the outcomes of young adults who tested positive for SARS-CoV-2 [8, 19]. For example, 2.5% of those aged 20–29 years old who were diagnosed with SARS-CoV-2 in Indiana have been sick enough to be hospitalized. However, as is discussed below, the severity of illness for many infectious agents is dose dependent. Thus, the truth of the matter is that no one can define the risks of SARS-CoV-2 human challenges because we do not know the dose of SARS-CoV-2 that causes severe infection in young healthy persons.

If we have learned anything from human infection experiments, for several pathogens outcome is clearly dose dependent. For example, in our Haemophilus ducreyi skin infection model, volunteers develop infection (papules) at almost all inoculated sites in the 1–150 colony-forming unit (CFU) dose range; in 30% of the volunteers, all papules spontaneously resolve, whereas abscesses form in 70% of the volunteers [20]. This host effect is reproducible when the volunteers are challenged a second time [21]. For doses >150 CFUs, the host effect on outcome is lost in that abscesses develop at all sites; for doses >1000 CFUs, abscesses form too rapidly to mimic natural infection [20, 22]. In some models, the infectious dose is strain dependent; for example, there is 100-fold difference in the median infective dose (ID 50) of 2 gonococcal strains used to infect male volunteers [23]. For the initial human trials done with coronavirus 229-E in 1967, the infectious dose that caused common colds in 66% of the volunteers was only 101.2 to 101.5 50% tissue culture infectious dose (TCID 50). Some have advocated that initial dose-ranging experiments for SARS-CoV-2 challenges should include doses of 1 × 10^2, 1 × 10^3, and 1 × 10^4 TCID 50 [2, 3], which are 3 logs lower than the doses used in recent influenza challenge models [24, 25]. However, if SARS-CoV-2 operates in a very low and narrow dose range similar to coronavirus 229-E, we may not be able to easily distinguish between doses that lead to asymptomatic or mild infection versus those that cause severe disease and death in young healthy volunteers.

CONCLUSIONS

The emerging data from phase III trials showing the high efficacy of the Pfizer, Moderna, and AstraZeneca vaccines in the prevention of disease due to SARS-CoV-2 lessen the argument for the development of a SARS-CoV-2 challenge model. However, proponents have stated that a challenge model may be needed to evaluate next-generation vaccines in the setting of low levels of circulating virus [2]. Nevertheless, we conclude that the risks of a wild-type SARS-CoV-2 human challenge model cannot be defined but are potentially substantial, and, at this time, severe disease cannot be adequately managed. Although to some it may seem paternalistic, according to our ethical codes, in the absence of curative therapy, even if a volunteer consents, sponsors, physicians, and scientists are bound to refuse to conduct such trials.

The SARS-CoV-2 pandemic has led to tremendous pressure to develop therapeutics and vaccines, which has resulted in premature acceptance of therapies, such as hydroxychloroquine, that proved to be toxic or not beneficial, because we did not follow longstanding rules of scientific rigor [26]. Similarly, the pandemic should not lead us to ignore or revise our longstanding codes of ethics regarding human subjects research.

Acknowledgments

We thank Byron Batteiger and Christopher Robinson for their thoughtful criticisms of the manuscript and the Rikers Debate Project, 1Day Sooner, and the Central Synagogue of Manhattan for stimulating discussion of this topic.

Financial support. This work was funded by the National Institutes of Allergy and Infectious Diseases (R01 AI1137116; to S. M. S.) and by National Center for Advancing Translational Sciences (UL1TR002529; to M. A. O.) at the National Institutes of Health.

Potential conflicts of interest. G. D. Z. reports personal fees from Sanofi Pasteur, Merck, and Moderna and research funding through Indiana University from Merck, outside the submitted work. M. A. O. reports personal fees from Merck
References

1. Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis 2020; 221:1752–6.
2. Baay M, Neels P. SARS-CoV-2 controlled human infection models: ethics, challenge agent production and regulatory issues. Biologicals 2020; 67:69–74.
3. Levine MM, Abdullah S, Arabi YM, et al. Viewpoint: establishing a closely-monitored challenge model of COVID-19 in healthy volunteers. Clin Infect Dis 2020; eiaa1290. doi: 10.1093/cid/eiaa1290
4. Eyal N, Lipsitch M, Smith PG. Response to Cioffi. J Infect Dis 2020; 222:169–70.
5. Eyal N, Lipsitch M, Smith PG. Response to Dawson et al. J Infect Dis 2020; 222:516–7.
6. Cioffi A. Coronavirus disease 2019: is everything lawful to create an effective vaccine? J Infect Dis 2020; 222:169.
7. Dawson L, Earl J, Livezey J. Severe acute respiratory syndrome coronavirus 2 human challenge trials: too risky, too soon. J Infect Dis 2020; 222:514–6.
8. Spinola SM, Zimet GD, Ott MA, Katz BP. Human challenge studies are unlikely to accelerate coronavirus vaccine licensure due to ethical and practical issues. J Infect Dis 2020; 222:1572–4.
9. Kelland K. Britain moves closer to Covid-19 vaccine trials that infect volunteers. Reuters. Available at: https://www.reuters.com/article/health-coronavirus-challenge-virus-update-1-britain-moves-closer-to-covid-19-vaccine-trials-that-infect-volunteers-idUKL8N2HF736. Accessed 16 October 2020.
10. Steinbuch Y. Thousands sign up to be exposed to COVID after getting experimental vaccine. New York Post. Available at: https://nypost.com/2020/10/12/thousands-sign-up-to-be-vaccinated-then-exposed-to-covid-19/. Accessed 12 October 2020.
11. McKeever V. Volunteers in the UK will reportedly be exposed to the coronavirus to speed up vaccine development. CNBC. Available at: https://www.cnbc.com/2020/09/23/volunteers-in-the-uk-will-reportedly-be-the-fire-exposed-to-speed-up-vaccine-development.html. Accessed 23 September 2020.
12. Parker L. To find a vaccine for COVID-19, will we have to deliberately infect people? National Geographic. Available at: https://www.nationalgeographic.com/science/2020/09/to-make-a-coronavirus-vaccine-we-may-need-to-deliberately-infect-people/. Accessed 16 September 2020.
13. Deming ME, Michael NL, Robb M, et al. Accelerating development of SARS-CoV-2 vaccines—the role for controlled human infection models. N Engl J Med 2020; 383:e63.
14. WHO Working Group for Guidance on Human Challenge Studies in COVID-19. Key criteria for the ethical acceptability of COVID-19 human challenge studies. Geneva: World Health Organization; 2020.
15. Vollmann J, Winau R. Informed consent in human experimentation before the Nuremberg code. BMJ 1996; 313:1445–9.
16. World Medical Association. WMA declaration of Helsinki - ethical principles for medical research involving human subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 29 August 2020.
17. Department of Health, Education, and Welfare. The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. 1979. Available at: https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html. Accessed 29 August 2020.
18. Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis 2001; 33:1028–33.
19. Tenforde MW, Kim SS, Lindsell CJ, et al.; IVY Network Investigators; CDC COVID-19 Response Team; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69:993–8.
20. Janowicz DM, Other N, Katz BP, Spinola SM. Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience. J Infect Dis 2009; 199:1671–9.
21. Spinola SM, Beng CT, Faber AL, et al. Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection. Infect Immun 2003; 71:6658–63.
22. Spinola SM, Wild LM, Apicella MA, et al. Experimental human infection with Haemophilus ducreyi. J Infect Dis 1994; 169:1146–50.
23. Hobbs MM, Spaulding PE, Cohen MS, et al. Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mKC. Front Microbiol 2011; 2:1–12.
24. Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdm09: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015; 60:693–702.
25. Han A, Czajkowski LM, Donaldson A, et al. A dose-finding study of a wild-type influenza A(H3N2) virus in a healthy volunteer human challenge model. Clin Infect Dis 2019; 69:2082–90.
26. Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020; 172:819–21.